GlassScriptPhysician profile
Michael S Mayron
NPI 1790788834
$10,548.29
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,028 · 2020: $3,893 · 2021: $3,515 · 2022: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,047.66 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $789.51 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $787.92 | 2019-2021 | |
| Amgen INC. | $589.57 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $521.39 | 2019-2021 | |
| Abbvie INC. | $517.09 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $512.91 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $506.34 | 2019-2021 | |
| Biogen, INC. | $502.09 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $380.33 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $373.94 | 2019-2021 | |
| Ucb, INC. | $289.33 | 2019-2021 | |
| Allergan, INC. | $285.72 | 2020 | |
| Amneal Pharmaceuticals LLC | $267.75 | 2019-2021 | |
| Lilly USA, LLC | $260.54 | 2019-2021 |
Show all 43 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mayron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.